Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01888978 · ClinicalTrials.gov registry record · Phase 2
Molecularly Tailored Therapy for Pancreas Cancer
A Phase 2 study of Pancreatic Cancer, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT01888978: Completed Phase 2 study of Pancreatic Cancer, sponsored by Georgetown University.
NCT01888978 is a Phase 2 study of Pancreatic Cancer that has completed, run by Georgetown University. The registered enrollment target is 19 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01888978, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
Patient therapy is tailored according to the molecular profile of the patient's tumor.
Primary Outcome
The number of days from study entry to biopsy to molecular results to first dose
Conditions Studied
Interventions
- DRUG Gem-OX
- DRUG Gem-5FU
- DRUG Gem-Tax
- DRUG Modified FOLFOX-6
- DRUG Ox-Tax
Study Locations (2)
District of Columbia
- Georgetown University- Lombardi Comprehensive Cancer Center - Washington D.C.
Maryland
- MedStar Montgomery Medical Center - Olney
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-12 |
| Est. Completion | 2018-01-24 |
| Phase | Phase 2 |
What the finished NCT01888978 record still lists
NCT01888978 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Gem-OX is the first listed.
NCT01888978 reports a single indexed study location in District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT01888978 about?
NCT01888978 is a clinical study titled "Molecularly Tailored Therapy for Pancreas Cancer". Patient therapy is tailored according to the molecular profile of the patient's tumor.
What is the current status of trial NCT01888978?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2012-12. Estimated completion is 2018-01-24.
What conditions does trial NCT01888978 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT01888978?
The interventions under investigation include: Gem-OX (DRUG), Gem-5FU (DRUG), Gem-Tax (DRUG), Modified FOLFOX-6 (DRUG), Ox-Tax (DRUG).
Who is sponsoring clinical trial NCT01888978?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01888978 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01888978's enrollment target sits among peer trials
19 233rd of 278 higher than 45 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia